Integrated Quantitative Investments LLC Acquires New Holdings in Illumina, Inc. $ILMN

Key Points

• Integrated Quantitative Investments opened a new position in Illumina of 11,916 shares (~$1.13M) in Q3, while several other institutional managers (e.g., ARK, Amova, Dimensional) also boosted stakes—institutional ownership now stands at 89.42%.
• Illumina beat quarterly estimates (EPS $1.35 vs. $1.26 est.; revenue $1.16B vs. $1.10B), set FY2026 guidance of 5.050–5.200 EPS, but the stock carries a consensus "Hold" rating with an average target of $129.69.

Integrated Quantitative Investments LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 11,916 shares of the life sciences company's stock, valued at approximately $1,132,000.

Other hedge funds also recently made changes to their positions in the company. Amova Asset Management Americas Inc. grew its stake in Illumina by 5.7% in the third quarter. Amova Asset Management Americas Inc. now owns 917,246 shares of the life sciences company's stock valued at $87,028,000 after acquiring an additional 49,265 shares during the period. ARK Investment Management LLC boosted its position in Illumina by 25.7% during the 3rd quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company's stock valued at $139,405,000 after buying an additional 299,801 shares during the period. Dimensional Fund Advisors LP boosted its position in Illumina by 14.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 557,525 shares of the life sciences company's stock valued at $52,926,000 after acquiring an additional 69,997 shares in the last quarter. Legato Capital Management LLC lifted its position in Illumina by 5.9% during the third quarter. Legato Capital Management LLC now owns 25,000 shares of the life sciences company's stock valued at $2,374,000 after buying an additional 1,400 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of Illumina by 20.7% in the 3rd quarter. Victory Capital Management Inc. now owns 58,446 shares of the life sciences company's stock worth $5,551,000 after purchasing an additional 10,031 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of recent research reports. Evercore set a $150.00 target price on Illumina in a research note on Friday, February 6th. Weiss Ratings restated a "hold (c-)" rating on shares of Illumina in a research note on Monday, December 29th. Robert W. Baird set a $137.00 target price on shares of Illumina in a research note on Friday, February 6th. TD Cowen reissued a "hold" rating on shares of Illumina in a research report on Wednesday, January 7th. Finally, Barclays increased their target price on Illumina from $100.00 to $110.00 and gave the company an "underweight" rating in a research note on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of "Hold" and an average target price of $129.69.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 2,370 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company's stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is owned by corporate insiders.

Illumina Price Performance

Shares of ILMN opened at $128.97 on Thursday. The firm has a fifty day simple moving average of $134.74 and a two-hundred day simple moving average of $118.89. The firm has a market cap of $19.72 billion, a PE ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 1.45. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the business posted $0.95 EPS. The company's revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.